REG - Shield Therapeutics - PDMR Transaction Notification

Shield TherapeuticsAnnouncement

13/02/2025 16:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250213:nRSM0703Xa&default-theme=true

RNS Number : 0703X  Shield Therapeutics PLC  13 February 2025

 

Shield Therapeutics plc

("Shield Therapeutics" or the "Company")

 

PDMR Transaction Notification

 

London, UK, 13 February 2025: Shield Therapeutics plc (LSE:STX), a commercial
stage pharmaceutical company specialising in iron deficiency, confirms that Mr
Anders Lundstrom, Chief Executive Officer, acquired 575,000 Ordinary Shares in
the Company on 13 February 2025 at a price of 3.7p per share. Mr Lundstrom now
holds a beneficial interest in 585,000 Ordinary Shares.

 

The notification below, which has been made in accordance with the
requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them:

 

 1.                            Details of the person discharging managerial responsibilities / person closely
                               associated
 a.                            Name                                      Anders Lundstrom
 2.                            Reason for the notification
 a.                            Position/status                           Chief Executive Officer
 b.                            Initial notification                      Initial

                               /Amendment
 3.                            Details of the issuer, emission allowance market participant, auction
                               platform, auctioneer or auction monitor
 a.                            Name                                      Shield Therapeutics plc
 b.                            LEI                                       213800G74QWY15FC3W71
 4.                            Details of the transaction(s): section to be repeated for (i) each type of
                               instrument; (ii) each type of transaction; (iii) each date; and (iv) each
                               place where transactions have been conducted
 a.                            Description of the                        Ordinary shares of 1.5p each in the capital of the Company

                               Financial instrument, type

                               of instrument

                               Identification code

                                                                         ISIN of Ordinary Shares: GB00BYV81293
 b.                            Nature of the transaction                 Acquisition of Ordinary Shares

 c.                            Price(s) and volume(s)

Price(s)  Volume(s)

                                                                         3.7p      575,000
 d.                            Aggregated information

                               ·      Aggregated volume                  575,000

                               ·      Price

                                                                         £21,275

 e.                            Date of the transaction                   13 February 2025
 f.                            Place of the transaction                  AIM

d.

Aggregated information

·      Aggregated volume

·      Price

 

 

575,000

 

£21,275

 

e.

Date of the transaction

13 February 2025

f.

Place of the transaction

AIM

 

 

 

For further information please contact:

 

 Shield Therapeutics plc                                                                        www.shieldtherapeutics.com (http://www.shieldtherapeutics.com/)
 Anders Lundstrom, CEO                                                                          +44 (0) 191 511 8500

 Santosh Shanbhag, CFO                                                                          Investorrelations@shieldtx.com

 Stephanie Hicks, Investor Relations

 Nominated Adviser and Joint Broker
 Peel Hunt LLP
 James Steel / Patrick Birkholm                                                                 +44 (0)20 7418 8900

 Joint Broker                                                                                   +44 (0)20 7220 0500
 Cavendish Ltd
 Geoff Nash / Rory Sale / Nigel Birks / Harriet
 Ward

 Financial PR & IR Advisor
 Walbrook PR
 Alice Woodings / Lianne Applegarth                                                             +44 (0)20 7933 8780 or shield@walbrookpr.com (mailto:shield@walbrookpr.com)

 

About Iron Deficiency and ACCRUFeR®/FeRACCRU®

Clinically low iron levels (aka iron deficiency, ID) can cause serious health
problems for adults of all ages, across multiple therapeutic areas. Together,
ID and ID with anemia (IDA) affect about 20 million people in the US and
represent a $2.3B market opportunity. As the first and only FDA approved oral
iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet
medical need for both physicians and patients.

 

ACCRUFeR®/FeRACCRU® (ferric maltol) is a novel, stable, non-salt-based oral
therapy for adults with ID/IDA. The drug has a novel mechanism of absorption
compared to other oral iron therapies and has been shown to be an efficacious
and well-tolerated therapy in a range of clinical trials. More information
about ACCRUFeR®/FeRACCRU®, including the product label, can be found at:
www.accrufer.com (http://www.accrufer.com) and www.feraccru.com
(http://www.feraccru.com) .

 

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company that delivers
ACCRUFeR®/FeRACCRU® (ferric maltol), an innovative and differentiated
pharmaceutical product, to address a significant unmet need for patients
suffering from iron deficiency, with or without anemia. The Company has
launched ACCRUFeR® in the U.S. with an exclusive, multi-year collaboration
agreement with Viatris Inc. Outside of the U.S., the Company has licensed the
rights to four specialty pharmaceutical companies. FeRACCRU® is
commercialized in the UK and European Union by Norgine B.V., which also has
marketing rights in Australia and New Zealand. Shield also has an exclusive
license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the
development and commercialization of ACCRUFeR®/ FeRACCRU® in China, Hong
Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea,
and with KYE Pharmaceuticals Inc. for Canada.

 

ACCRUFeR®/FeRACCRU® has patent coverage until the mid-2030s.

ACCRUFeR®/FeRACCRU® are registered trademarks of Shield Therapeutics.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHEAKADFESSEFA